Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder

BJU International

Volumn 96, Issue 6, 2005, Pages 803-805

  Ang, Celina ^a   Chambers, Ann F ^a   Tuck, Alan B ^a   Winquist, Eric ^a   Izawa, Jonathan I ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Bladder carcinoma; Osteopontin; Prognosis

Indexed keywords

OSTEOPONTIN;

AGED; BLADDER CARCINOMA; CANCER STAGING; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; REVIEW; TRANSITIONAL CELL CARCINOMA;

AGED; CARCINOMA, TRANSITIONAL CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; NEOPLASM STAGING; OSTEOPONTIN; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; SIALOGLYCOPROTEINS; URINARY BLADDER NEOPLASMS;

EID: 25844431605     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05716.x     Document Type: Review

References (12)

1. Lee R, Droller MJ. The natural history of bladder cancer. Urol Clin North Am 2000; 27: 1-13
2. Furger KA, Menon RK, Tuck AB, Bramwell VH, Chambers AF. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1: 621-32
3. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004; 90: 1877-81
4. Singhal H, Bautista DS, Tonkin KS et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-11
5. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95: 506-12
6. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-6
7. Coppola D, Szabo M, Boulware D et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184-90
8. Khan SR, Johnson JM, Peck AB, Cornelius JG, Glenton PA. Expression of osteopontin in rat kidneys: induction during ethylene glycol induced calcium oxalate nephrolithiasis. J Urol 2002; 168: 1173-81
9. Nau GJ, Chupp GL, Emile JF et al. Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am J Path 2000; 157: 37-42
10. Bautista DS, Denstedt J, Chambers AF, Harris JF. Low-molecular-weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem 1996; 61: 402-9
11. Bautista DS, Saad Z, Chambers AF et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin Biochem 1996; 29: 231-9
12. Fisher LD, van Belle G. Biostatistics. New York: John Wiley Et Sons 1993: 786-843